NCT00749021已完成1 期
A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.
Clement K. Chan3 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2008年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 3
- 主要终点
- Mean change in Best Corrected Visual Acuity from baseline measured at 4 meters on the ETDRS chart at 12 months.
研究概览
简要总结
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is 50 years or older
- •Patient is willing to participate in this study and to follow the criteria and protocol of this study.
- •Patient is not involved with another clinical trial.
- •Ability to understand the informed consent and willingness to sign the consent.
- •Presence of a submacular vascularized or fibrovascular PED. Central foveal involvement by the PED or the CNV due to age related macular degeneration.
- •PED less than or equal to 12 disc area in size
- •BCVA with ETDRS of greater than or equal to 19 letters and less than or equal to 69 letters (20/400 to 20/40)
- •Central 1-mm foveal thickness of greater than or equal to 250 microns on OCT.
- •Greatest linear diameter of the submacular hemorrhage needs to be less than 50% of the entire PED.
- •Submacular fibrosis needs to be less than 50% of the entire PED.
- •Sufficiently clear media (cornea, anterior chamber, lens, vitreous) for OCT, FA, and FP.
- •Intraocular pressure of 25 mm or less in the study eye, with or without use of ocular hypotensive agents.
排除标准
- •Pregnancy or lactation
- •Premenopausal women not using adequate contraception
- •Known serious allergies to ranibizumab, fluorescein dye, drug for pupillary dilation, topical anesthetic, sterilizing solution
- •Contraindication to pupillary dilation in study eye
- •Any condition (including inability to read visual acuity charts or language barrier) that may preclude patient's ability to comply with the study protocol requirements
- •Presence of any advanced systemic condition or endstage disease, advanced Alzheimer syndrome, endstage cancer, etc., which will likely prevent patient from completing study.
- •Previous therapeutic radiation in the region of the study eye.
- •Prior anti-vascular endothelial factor therapy within 30 days.
- •More than 3 sessions of prior anti-VEGF therapy.
- •More than 1 prior photodynamic therapy (PDT)
- •Prior triamcinolone in the past 6 months or dexamethasone in the past 1 month.
- •Prior retinal pigment epithelial (RPE) tear in study eye.
- •Prior ocular surgery (except YAG laser capsulotomy) for study eye within past 90 days.
- •Anticipated ocular surgery (except YAG laser capsulotomy) for the next 12 months.
- •Prior therapy for AMD (except minerals and vitamins), including laser, within the past 30 days.
- •Prior intraocular or periocular corticosteroid therapy within the past 120 days
- •Prior vitrectomy
- •Presence of any causes of CNV and PED other than due to AMD.
- •Presence of any substantial ocular disease (other than CNV and PED) that may compromise vision in the study eye and/or confound interpretation of the date; e.g. substantial cataracts, concomitant diabetic retinopathy affecting the macula, advanced glaucoma, optic neuritis, optic neuropathy or atrophy, marked macular atrophy, ocular vascular occlusion, history of retinal detachment, uveitis, viral or other forms of chorioretinitis, etc.
- •Presence of ocular disease other than AMD affecting study eye, i.e. presumed ocular histoplasmosis syndrome, angioid streaks, pathologic myopia (spherical equivalent of greater than or equal to -8 diopters of myopia or axial length of greater than or equal to 25 mm), choroidal rupture, multifocal choroiditis, etc.
- •Active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at screening or Day 0.
研究组 & 干预措施
Regimen 1
Active Comparator
Intravitreal injection of Ranibizumab monthly for 12 months.
干预措施: Ranibizumab (Drug)
Regimen 2
Active Comparator
Intravitreal injection of ranibizumab for 4 months (at Day 0, Month 1, Month 2, and Month 3) followed by by treatments on predefined re-treatment criteria.
干预措施: Ranibizumab (Drug)
Regimen 3
Active Comparator
Intravitreal injection of Ranibizumab 2.0mg monthly for 12 months
干预措施: Ranibizumab (Drug)
Regimen 4
Active Comparator
Intravitreal injection 2.0mg ranibizumab for 4 months (at Day 0, Month 1 and Month 2, and Month 3) followed by PRN treatments on pre-defined re-treatment criteria
干预措施: Ranibizumab (Drug)
结局指标
主要结局
Mean change in Best Corrected Visual Acuity from baseline measured at 4 meters on the ETDRS chart at 12 months.
时间窗: 12 months
次要结局
- Proportion of patients with an improvement from baseline in Contrast Sensitivity at 24 and 48 weeks(24 and 48 weeks)
- Status of fluorescein staining or leakage (increased or decreased) from baseline(12 months)
- Proportion of eyes reaching BCVA greater than or equal to 20/200(12 months)
- Proportion of eyes gaining greater than or equal to 0, 5, 10, and 15 letters on the ETDRS chart(12 months)
- Reduction in central macular thickness from baseline (central 1-mm subfield) as measured by an OCT(12 months)
- Changes in choroidal neovascular lesion (CNV)size on fluorescein angiography and fundus photography from baseline(12 months)
- Changes in retinal pigment epithelial detachment size on fluorescein angiography and fundus photography, including height of the PED and associated submacular fluid on OCT in comparison to baseline(12 months)
- Ocular safety outcome including ocular complication, i.e. RPE tears, uveitis, endophthalmitis(12 months)
- Systemic safety outcome including cardiovascular event, cerebral vascular events(12 months)
- Proportion of patients with an improvement from baseline in the VFQ overall composite score and near and distance activities subscales at 24 and 48 weeks(24 and 48 weeks)
研究者
Clement K. Chan
Principal Investigator
Southern California Desert Retina Consultants, MC
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic SarcomaSoft Tissue SarcomaNCT05821231Institut Claudius Regaud14
已完成
1 期
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCLDiffuse Large B-cell LymphomaNCT04134936MorphoSys AG66
招募中
1 期
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin LymphomaNon-hodgkin Lymphoma,B CellNCT05741359Bioray Laboratories18
终止
1 期
A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain TumorsPrimary Malignant Brain TumorNCT05892653ABM Therapeutics Shanghai Company Limited15
已完成
1 期
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid TumorsHigh-grade Serous Ovarian CancerSolid TumorsNUT Midline CarcinomaTriple-Negative Breast CancerNCT02307240Curis, Inc.43